ZHEJIANG HISUN PHARMACEUTI

Jiangsu Hisun Pharma Q3 Earnings Surge: API Expansion Drives 15.8% Profit Growth

Explore Zhejiang Hisun Pharmaceutical’s Q3 earnings surge: 15.8% profit jump driven by API growth, strategic expansions, and steady stock performance.

Samantha Roth

23/10/2026, 12:57

3 minutes to read

Zhejiang Hisun Pharmaceutical Surges 18.6% YTD as New Drugs Boost Growth

Discover how Zhejiang Hisun Pharmaceutical’s latest earnings preview and expanding drug pipeline are positioning it for growth in China’s thriving pharma market.

Jake Connors

22/10/2026, 21:50

3 minutes to read

Hisun Pharma Eyes Strong Q4 Outlook as Shares Stabilize Near 200‑Day Support

Explore how Zhejiang Hisun Pharmaceutical’s solid quarter‑year outlook and expanding drug portfolio are driving steady stock performance amid market volatility.

Jake Connors

21/10/2026, 23:10

3 minutes to read

Hisun Pharma Q1 2026: Profit Surge, Pet‑Health Growth, and Divestiture Boost

Q1 2026 earnings boost for Zhejiang Hisun Pharmaceutical (600267.SS) shows higher net profit, stronger drug sales and pet‑health growth – a clear path to rising margins.

Samantha Roth

20/10/2026, 17:22

3 minutes to read